Molecule
Gadobenate is a gadolinium-based contrast agent indicated for intravenous use in magnetic resonance imaging (MRI) of the central nervous system (CNS) in adults and pediatric patients (including term neonates), among other approved uses. MedsAcross supplies Gadobenate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
magnetic resonance imaging (MRI) of the central nervous system (CNS) in adults and pediatric patients (including term neonates), to visualize lesions with abnormal blood-brain barrier or abnormal vascularity of the brain, spine, and associated tissues. magnetic resonance angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease.
Source: US FDA prescribing information
Gadobenate dimeglumine is a paramagnetic agent and, as such, develops a magnetic moment when placed in a magnetic field. The large magnetic moment produced by the paramagnetic agent results in a large local magnetic field, which can enhance the relaxation rates of water protons in its vicinity leading to an increase of signal intensity (brightness) of tissue. In magnetic resonance imaging (MRI), visualization of normal and pathological tissue depends in part on variations in the radiofrequency signal intensity that occur with 1) differences in proton density, 2) differences of the spin-lattice or longitudinal relaxation times (T1), and 3) differences in the spin-spin or transverse relaxation time (T2). When placed in a magnetic field, gadobenate dimeglumine decreases the T1 and T2 relaxation time in target tissues.
Source: US FDA prescribing information
The recommended dose of MultiHance is 0.2 mL/kg (0.1 mmol/kg) administered as a rapid bolus intravenous injection. For MRI of the CNS in pediatric patients below 2 years of age the recommended dosage range is 0.1 to 0.2 mL/kg. To ensure complete injection of the contrast medium, follow the injection with a saline flush of at least 5 mL in MRI of the CNS and at least 20 mL in MRA.
Source: US FDA prescribing information
MultiHance is contraindicated in patients with known allergic or hypersensitivity reactions to gadolinium-based contrast agents.
Source: US FDA prescribing information
Boxed warning (risk associated with intrathecal use and nephrogenic systemic fibrosis): Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. MultiHance is not approved for intrathecal use. Hypersensitivity: anaphylactic/anaphylactoid reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe reactions including shock can occur. Monitor patients closely for need of emergency cardiorespiratory support. Gadolinium is retained for months or years in brain, bone, and other organs.
Source: US FDA prescribing information
The following adverse reactions are discussed in greater detail in other sections of the label: Nephrogenic systemic fibrosis Hypersensitivity reactions The most commonly reported adverse reactions are nausea (1.3%) and headache (1.2%).
Source: US FDA prescribing information
Transporter-Based Drug-Drug Interactions MultiHance and other drugs may compete for the canalicular multispecific organic anion transporter (MOAT also referred to as MRP2 or ABCC2). Therefore MultiHance may prolong the systemic exposure of drugs such as cisplatin, anthracyclines (e.g. doxorubicin, daunorubicin), vinca alkaloids (e.g. vincristine), methotrexate, etoposide, tamoxifen, and paclitaxel. In particular, consider the potential for prolonged drug exposure in patients with decreased MOAT activity (e.g. Dubin Johnson syndrome).
Source: US FDA prescribing information
Store at 25°C (77°F), excursions permitted to 15-30°C (59-86°F). Do not freeze.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
6 presentations of Gadobenate, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| MultiHance 10580 mg/20 mL injectionIntravenous | Bracco Diagnostics | US FDA | Available on request |
| MultiHance 2645 mg/5 mL injectionIntravenous | Bracco Diagnostics | US FDA | Available on request |
| MultiHance 26450 mg/50 mL injectionIntravenous | Bracco Diagnostics | US FDA | Available on request |
| MultiHance 5290 mg/10 mL injectionIntravenous | Bracco Diagnostics | US FDA | Available on request |
| MultiHance 52900 mg/100 mL injectionIntravenous | Bracco Diagnostics | US FDA | Available on request |
| MultiHance 7935 mg/15 mL injectionIntravenous | Bracco Diagnostics | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 23 November 2004 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 6 presentations of Gadobenate and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Gadobenate, including MultiHance.
Yes. The US FDA first approved Gadobenate on 23 November 2004, according to Drugs@FDA.
No listed presentation of Gadobenate is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.